Ace inhibition versus angiotensin type 1 receptor antagonism: Differential effects on PAI-1 over time

Hypertension

Volumn 40, Issue 6, 2002, Pages 859-865

  Brown, Nancy J ^a,b   Kumar, Sandeep ^a   Painter, Corrie A ^b   Vaughan, Douglas E ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Angiotensin converting enzyme; Fibrin; Plasminogen; Renin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LOSARTAN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOCRINOLOGY; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; METABOLISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE SYMPORTER INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0036899135     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000040264.15961.48     Document Type: Article

References (45)

1. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJJr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327:669-677.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
3. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
4. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type I receptor in vivo. Kidney Int. 2000;58:251-259.
5. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
6. Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher PM, Sobel BE. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol. 1997; 17:3294-3301.
7. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
8. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78:656-660.
9. Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin. Diabetologia. 1901;44:1121-1124.
10. Sakamoto T, Woodcock-Mitchell J, Marutsuka K, Mitchell JJ, Sobel BE, Fujii S. TNF-α, and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol. 1999; 276:C1391-C1397.
11. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98: 2241-2247.
12. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971.
13. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and PAI-1 in humans. J Clin Endocrinol Metab. 2002;87:448-452.
14. Lottermoser K, Hertfelder HJ, Vetter H, Dusing R. Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens. 2000;13:359-363.
15. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 2002;105:304-309.
16. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U, Turgan C, Caglar S. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens. 1999;12:1071-1076.
17. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA, on behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
18. 1 receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol. 2000;20: 2297-2302.
19. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
20. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int. 1999;56:461-470.
21. Brown NJ, Agirbasli MA, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285-290.
22. Fogari R, Zoppi A, Malamani G, Marasi G, Pesce RM, Banderali A, Mugellini A. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res Clin Exp. 2001;62:68-78.
23. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension. 1996;27: 1299-1304.
24. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation. 1999;99:2983-2985.
25. Todd PA, Benfield P, Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs. 1990; 39:110-135.
26. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992;51: 513-521.
27. Matthews DR, Hasker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: Insulin resistance and β-cell function from plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
28. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
29. Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med. 1965;120:399-403.
30. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22: 579-784.
31. Vanhoutte PM. Endothelium and control of vascular function. Hypertension. 1989;13:658-667.
32. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells: Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998;18:1771-1779.
33. Katoh M, Egashira K, Mitsui T, Takeshita A, Narita H. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol. 2000;35:932-936.
34. 2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
35. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
36. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type 1 (PAI-1) complex relationship to elevated tPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.
37. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 1997;46:1950-1957.
38. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
39. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
40. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
41. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative SG. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001;345:851-860.
42. Brenner BM, Cooper ME, de ZD, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
43. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
44. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13:305-314.
45. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.